Symbols / TYRA Stock $33.79 -3.64% Tyra Biosciences, Inc.

Healthcare • Biotechnology • United States • NMS
TYRA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Todd Harris Ph.D.
Exch · Country NMS · United States
Market Cap 2.01B
Enterprise Value 1.57B
Income -119.95M
Sales —
FCF (ttm) -54.55M
Book/sh 4.83
Cash/sh 4.75
Employees 87
Insider 10d —
IPO Sep 15, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -13.17
PEG —
P/S —
P/B 7.00
P/C —
EV/EBITDA -11.87
EV/Sales —
Quick Ratio 14.25
Current Ratio 14.67
Debt/Eq 2.24
LT Debt/Eq —
EPS (ttm) -2.01
EPS next Y -2.57
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-02
ROA -25.68%
ROE -39.83%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 59.49M
Shs Float 28.38M
Insider Own 2.69%
Instit Own 93.89%
Short Float 23.95%
Short Ratio 7.36
Short Interest 7.71M
52W High 40.65
vs 52W High -16.89%
52W Low 8.75
vs 52W Low 286.11%
Beta 0.96
Impl. Vol. 3.13%
Rel Volume 1.07
Avg Volume 1.09M
Volume 1.16M
Target (mean) $51.24
Tgt Median $53.00
Tgt Low $37.00
Tgt High $59.62
# Analysts 11
Recom Strong_buy
Prev Close $35.06
Price $33.78
Change -3.64%
About

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$51.24
Mean price target
2. Current target
$33.79
Latest analyst target
3. DCF / Fair value
$-16.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$33.79
Low
$37.00
High
$59.62
Mean
$51.24

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-15 init Guggenheim — → Buy $54
2026-04-06 init Canaccord Genuity — → Buy $50
2026-03-20 main Piper Sandler Overweight → Overweight $56
2026-02-24 init Cantor Fitzgerald — → Overweight —
2026-02-17 main HC Wainwright & Co. Buy → Buy $45
2026-02-13 main Wedbush Outperform → Outperform $53
2026-02-03 main Oppenheimer Outperform → Outperform $50
2026-02-03 main Jefferies Buy → Buy $43
2026-01-28 init Barclays — → Overweight $59
2026-01-23 main Piper Sandler Overweight → Overweight $42
2025-12-16 main Wedbush Outperform → Outperform $37
2025-09-03 init Raymond James — → Strong Buy $35
2025-08-22 reit HC Wainwright & Co. Buy → Buy $30
2025-07-01 reit HC Wainwright & Co. Buy → Buy $30
2025-03-31 reit HC Wainwright & Co. Buy → Buy $30
2025-02-18 reit HC Wainwright & Co. Buy → Buy $30
2025-01-13 reit HC Wainwright & Co. Buy → Buy $30
2025-01-07 init UBS — → Buy $28
2024-11-11 main HC Wainwright & Co. Buy → Buy $30
2024-10-29 reit HC Wainwright & Co. Buy → Buy $32
News
RSS: Latest TYRA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-26 KAPLAN GILLA Director — 67,467 $2.25 $151,801
2026-03-25 KAPLAN GILLA Director — 14,295 $36.97 $528,506
2026-03-13 HARRIS TODD JAMES Chief Executive Officer — 1,463 $36.22 $52,990
2026-03-13 FUHRMAN ALAN CPA Chief Financial Officer — 1,376 $36.22 $49,839
2026-02-12 BENSEN DANIEL Officer — 8,000 $31.50 $262,965
2026-01-12 BENSEN DANIEL Officer — 8,000 $28.44 $228,186
2025-12-19 MORE ROBERT J Director — 10,000 $25.00 $250,000
2025-12-12 BENSEN DANIEL Officer — 8,000 $22.64 $181,159
2025-11-21 MORE ROBERT J Director — 246,871 $20.25 $5,000,026
2025-11-19 BENSEN DANIEL Chief Operating Officer — 125,589 $16.07 $2,030,923
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
132.76
+27.44%
104.18
+30.31%
79.94
+35.67%
58.93
Research And Development
102.93
+28.54%
80.08
+28.09%
62.52
+45.36%
43.01
Selling General And Administration
29.83
+23.79%
24.10
+38.29%
17.43
+9.47%
15.92
General And Administrative Expense
29.83
+23.79%
24.10
+38.29%
17.43
+9.47%
15.92
Other Gand A
29.83
+23.79%
24.10
+38.29%
17.43
+9.47%
15.92
Total Expenses
132.76
+27.44%
104.18
+30.31%
79.94
+35.67%
58.93
Operating Income
-132.76
-27.44%
-104.18
-30.31%
-79.94
-35.67%
-58.93
Total Operating Income As Reported
-132.76
-27.44%
-104.18
-30.31%
-79.94
-35.67%
-58.93
EBITDA
-132.22
-27.55%
-103.66
-30.24%
-79.59
-35.74%
-58.63
Normalized EBITDA
-132.22
-27.55%
-103.66
-30.24%
-79.59
-35.74%
-58.63
Reconciled Depreciation
0.55
+5.20%
0.52
+45.38%
0.36
+20.61%
0.30
EBIT
-132.76
-27.44%
-104.18
-30.31%
-79.94
-35.67%
-58.93
Net Income
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Pretax Income
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Net Non Operating Interest Income Expense
12.81
-27.58%
17.70
+63.69%
10.81
+196.03%
3.65
Net Interest Income
12.81
-27.58%
17.70
+63.69%
10.81
+196.03%
3.65
Interest Income Non Operating
12.81
-27.58%
17.70
+63.69%
10.81
+196.03%
3.65
Interest Income
12.81
-27.58%
17.70
+63.69%
10.81
+196.03%
3.65
Other Income Expense
—
—
-0.04
+22.00%
-0.05
Other Non Operating Income Expenses
—
—
-0.04
+22.00%
-0.05
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Net Income From Continuing Operation Net Minority Interest
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Net Income From Continuing And Discontinued Operation
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Net Income Continuous Operations
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Normalized Income
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Net Income Common Stockholders
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Diluted EPS
—
-1.51
+6.79%
-1.62
-22.73%
-1.32
Basic EPS
—
-1.51
+6.79%
-1.62
-22.73%
-1.32
Basic Average Shares
—
57.22
+33.98%
42.70
+1.96%
41.88
Diluted Average Shares
—
57.22
+33.98%
42.70
+1.96%
41.88
Diluted NI Availto Com Stockholders
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Line Item Trend 2021-12-31
Total Assets
—
Current Assets
—
Cash Cash Equivalents And Short Term Investments
—
Cash And Cash Equivalents
—
Other Short Term Investments
—
Prepaid Assets
1.88
Other Current Assets
—
Total Non Current Assets
—
Net PPE
—
Gross PPE
—
Accumulated Depreciation
-0.17
Properties
0.00
Buildings And Improvements
—
Machinery Furniture Equipment
0.18
Other Properties
—
Leases
0.14
Other Non Current Assets
—
Total Liabilities Net Minority Interest
—
Current Liabilities
—
Payables And Accrued Expenses
—
Payables
—
Accounts Payable
—
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
1.28
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Total Non Current Liabilities Net Minority Interest
—
Long Term Debt And Capital Lease Obligation
—
Long Term Capital Lease Obligation
—
Other Non Current Liabilities
0.37
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
—
Common Stock Equity
—
Capital Stock
—
Common Stock
—
Preferred Stock
—
Share Issued
—
Ordinary Shares Number
—
Treasury Shares Number
1.10
Additional Paid In Capital
—
Retained Earnings
—
Gains Losses Not Affecting Retained Earnings
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
—
Total Capitalization
—
Working Capital
—
Invested Capital
—
Total Debt
—
Capital Lease Obligations
—
Net Tangible Assets
—
Tangible Book Value
—
Preferred Stock Equity
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-95.14
-36.36%
-69.77
-39.16%
-50.14
+0.29%
-50.28
Cash Flow From Continuing Operating Activities
-95.14
-36.36%
-69.77
-39.16%
-50.14
+0.29%
-50.28
Net Income From Continuing Operations
-119.95
-38.70%
-86.48
-25.09%
-69.13
-24.96%
-55.33
Depreciation Amortization Depletion
0.55
+5.20%
0.52
+45.38%
0.36
+20.61%
0.30
Depreciation
0.55
+5.20%
0.52
+45.38%
0.36
—
Depreciation And Amortization
0.55
+5.20%
0.52
+45.38%
0.36
+20.61%
0.30
Stock Based Compensation
28.01
+22.83%
22.80
+68.58%
13.53
+27.74%
10.59
Operating Gains Losses
—
—
0.00
+33.33%
0.00
Gain Loss On Sale Of PPE
—
—
0.00
+33.33%
0.00
Change In Working Capital
-1.63
-123.32%
-0.73
-111.46%
6.36
+208.77%
-5.85
Change In Prepaid Assets
-5.08
-2905.92%
-0.17
+94.01%
-2.82
+65.73%
-8.24
Change In Payables And Accrued Expense
3.37
+552.82%
-0.74
-107.94%
9.37
+297.50%
2.36
Change In Payable
—
—
—
2.36
Change In Account Payable
—
—
—
2.36
Change In Other Working Capital
0.08
-54.89%
0.18
+198.92%
-0.19
-647.06%
0.03
Investing Cash Flow
72.46
+173.64%
-98.40
+31.95%
-144.60
-25768.52%
-0.56
Cash Flow From Continuing Investing Activities
72.46
+173.64%
-98.40
+31.95%
-144.60
-25768.52%
-0.56
Net PPE Purchase And Sale
-0.14
+78.77%
-0.66
+13.77%
-0.77
-37.75%
-0.56
Purchase Of PPE
-0.14
+78.77%
-0.66
+13.77%
-0.77
-37.75%
-0.56
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-0.14
+78.77%
-0.66
+13.77%
-0.77
-37.75%
-0.56
Net Investment Purchase And Sale
72.60
+174.28%
-97.74
+32.05%
-143.84
0.00
Purchase Of Investment
-101.25
+61.59%
-263.62
-83.28%
-143.84
0.00
Sale Of Investment
173.86
+4.81%
165.88
0.00
—
Financing Cash Flow
8.10
-95.99%
202.14
+13051.40%
1.54
+143.20%
0.63
Cash Flow From Continuing Financing Activities
8.10
-95.99%
202.14
+13051.40%
1.54
+143.20%
0.63
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
0.00
-100.00%
199.58
0.00
0.00
Common Stock Payments
0.00
+100.00%
-0.42
0.00
—
Repurchase Of Capital Stock
0.00
+100.00%
-0.42
0.00
—
Proceeds From Stock Option Exercised
8.10
+216.78%
2.56
+66.36%
1.54
+143.20%
0.63
Net Other Financing Charges
—
—
—
—
Changes In Cash
-14.58
-142.93%
33.96
+117.58%
-193.21
-284.78%
-50.21
Beginning Cash Position
92.97
+57.55%
59.01
-76.60%
252.21
-16.60%
302.43
End Cash Position
78.39
-15.68%
92.97
+57.55%
59.01
-76.60%
252.21
Free Cash Flow
-95.28
-35.27%
-70.44
-38.36%
-50.91
-0.13%
-50.84
Interest Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-2.12
+63.99%
-5.88
-371.85%
-1.25
0.00
Common Stock Issuance
0.00
-100.00%
200.00
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
200.00
0.00
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category